OBJECTIVE: Endothelin-converting enzyme 1 (ECE-1) is a key regulatory enzyme in the proteolytic processing of Endothelin-1 (ET-1), a potent vasoactive peptide. In most vascular beds, ECE-1 localizes to endothelial cells, but has not been extensively studied in the human placenta. We sought to evaluate the expression and cellular localization of ECE-1 in normal and preeclamptic placentas. STUDY DESIGN: Placentas from normal (n¼6) and preeclamptic (n¼6) women, matched for gestational age, were collected and serially sectioned for immunofluorescence (IF) studies to localize ECE-1 expression. Cell type specific markers were used to identify the following cell types: endothelial, trophoblast, macrophage, smooth muscle and fibroblast cells. The samples were stained with antibodies for ECE-1 and tissue markers and counterstained with DAPI. Negative controls were stained with secondary antibodies and DAPI. Quantitative analysis of ECE-1 within placenta samples was performed by western blot and ELISA. RESULTS: Immunofluorescence studies confirmed ECE-1 expression within the stroma and villous spaces of intermediate and stem villi of human placentas. Localization of ECE-1 occurred occasionally with endothelial cells but not with the other cell types evaluated (Figure 1 ). IF studies suggested less ECE-1 expression in preeclamptic placentas. Western blot and ELISA showed significantly less ECE-1 in preeclamptic compared with normal placentas (Figure 2) . CONCLUSION: ECE-1 is expressed in the villous spaces of the human placenta. There is significantly less ECE-1 expression in preeclamptic versus normal placentas. ECE-1 likely plays an important role in vascular homeostasis in the placenta and may be protective against disorders of vascular dysfunction, such as preeclampsia. The lack of colocalization of ECE-1 suggests a secreted form of the enzyme, however further study is needed to confirm this. OBJECTIVE: Women diagnosed with preeclampsia (PEC) have a higher incidence of chronic hypertension (HTN), heart failure, stroke, and other forms of cardiovascular disease. We hypothesized parameters on echocardiography (ECHO) performed at diagnosis of PEC would be associated with subsequent cardiovascular risk. STUDY DESIGN: Women with PEC were prospectively recruited from the Johns Hopkins Health System between September 2014 e December 2015. We included singleton pregnancies > 23 weeks and diagnosis of PEC with severe features (PEC-SF) or PEC-SF superimposed on chronic HTN and excluded known maternal heart valve disease, previous cardiac surgery, known cardiomyopathy, pulmonary hypertension, history of pulmonary embolism, or interstitial lung disease. ECHO was performed at time of PEC-SF diagnosis. Participants were assessed for HTN 3 years after delivery, defined as systolic blood pressure (BP) >130 mmHg, diastolic BP > 80 mmHg, or on anti-hypertensive therapy. Outcome data were collected via phone and electronic medical records. Baseline differences were tested using parametric or non -parametric tests as appropriate; significance was defined as p-value < 0.0007 using Bonferroni's correction.
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